UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Date of Report (Date of earliest event reported): January 11, 2005
ATHEROGENICS, INC.
| Georgia | 0-31261 | 58-2108232 | ||
| (State or Other Juris- diction of Incorporation |
(Commission File Number) |
(IRS Employer Identification No.) |
||
8995 Westside Parkway
Alpharetta, GA 30004
Registrant’s telephone number, including area code: (678) 336-2500
Not applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01. Other Events | ||||||||
| Item 9.01. Financial Statements and Exhibits | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 UPDATED BUSINESS INFORMATION | ||||||||
| EX-99.2 UPDATED RISK FACTORS | ||||||||
Item 8.01. Other Events
Updated business information and “Risk Factors” relating to the Registrant is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ATHEROGENICS, INC. |
||||
| Date: January 11, 2005 | By: | /s/ Mark P. Colonnese | ||
| Mark P. Colonnese | ||||
| Senior Vice President of Finance and Administration and Chief Financial Officer | ||||